The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy

LEON LG, Funel N, Peters GJ, Avan A, Vistoli F, Boggi U, GIOVANNETTI E.
Clin Cancer Res 2016 [Epub ahead of print]

continue reading →

FacebookGoogle+LinkedInTumblrTwitterPrintFriendlyShare

Recent developments in the use of immunotherapy in non-small cell lung cancer

Santarpia M, GIOVANNETTI E, Rolfo C, Karachaliou N, González-Cao M, Altavilla G, Rosell R.
Expert Rev Respir Med. 2016 May 5. [Epub ahead of print]

continue reading →

FacebookGoogle+LinkedInTumblrTwitterPrintFriendlyShare

Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment

Le Large TY, Mato Prado M, Krell J, Bijlsma MF, Meijer LL, Kazemier G, Frampton AE, GIOVANNETTI E.
Expert Rev Mol Diagn. 2016 [Epub ahead of print]

continue reading →

FacebookGoogle+LinkedInTumblrTwitterPrintFriendlyShare

Prospective Validation of microRNA Signatures for Detecting Pancreatic Malignant Transformation in Endoscopic-Ultrasound Guided Fine-Needle Aspiration Biopsies

Frampton AE, Krell J, Mato Prado M, Gall TMH, Abbassi-Ghadi N, Del Vecchio Blanco G, Funel N, GIOVANNETTI E, Castellano L, Habib NA, Vlavianos P, Stebbing J, Jiao LR.
Oncotarget 2016 Apr 12 [Epub ahead of print]

continue reading →

FacebookGoogle+LinkedInTumblrTwitterPrintFriendlyShare

Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: a PAMM-EORTC perspective

Ciccolini J, Serdjebi C; Peters GJ, GIOVANNETTI E.
Cancer Chem Pharmacol  2016 Mar 23. [Epub ahead of print]

continue reading →

FacebookGoogle+LinkedInTumblrTwitterPrintFriendlyShare

Feasibility of cell-free circulating tumor DNA testing for lung cancer

Santarpia M, Karachaliou N, González-Cao M, Altavilla G, GIOVANNETTI E, Rosell R.
Biomark Med. 2016;10:417-30

continue reading →

FacebookGoogle+LinkedInTumblrTwitterPrintFriendlyShare

The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer

Passiglia F, Caparica R, GIOVANNETTI E, Giallombardo M, Listi A, Diana P, Cirrincione G, Caglevic C, Raez LE, Russo A, Rolfo C.
Exp Opin Invest New Drugs 2016;25:385-92

continue reading →

FacebookGoogle+LinkedInTumblrTwitterPrintFriendlyShare

On the pharmacogenetics of non-small cell lung cancer treatment

Santarpia MC, Rolfo C, Peters GJ, Leon LG, GIOVANNETTI E.
Expert Opin Drug Metab Toxicol. 2016;12:307-17

continue reading →

FacebookGoogle+LinkedInTumblrTwitterPrintFriendlyShare

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Klionsky DA, GIOVANNETTI E, et al.
Autophagy 2016;12:1-222

Link: www.ncbi.nlm.nih.gov/pubmed/26799652

FacebookGoogle+LinkedInTumblrTwitterPrintFriendlyShare

Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib

Muller IB, de Langen AJ, Honeywell RH, GIOVANNETTI E, Peters GJ.
Exp Rev Anticancer Ther 2016;16:147-57

continue reading →

FacebookGoogle+LinkedInTumblrTwitterPrintFriendlyShare